29-Jul-2026
Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX)
TipRanks (Mon, 27-Jul 5:00 AM ET)
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
PRNewswire (Tue, 21-Jul 7:29 PM ET)
PRNewswire (Sat, 18-Jul 2:55 PM ET)
Market Chameleon (Fri, 17-Jul 3:31 AM ET)
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
PRNewswire (Fri, 17-Jul 7:00 AM ET)
REGENXBIO Announces Proposed Public Offering of Common Stock
PRNewswire (Thu, 16-Jul 4:27 PM ET)
REGENXBIO Secures $100 Million Milestone as First Patient Dosed in Key Diabetic Retinopathy Trial
Market Chameleon (Mon, 29-Jun 4:37 AM ET)
PRNewswire (Mon, 29-Jun 7:05 AM ET)
Market Chameleon (Wed, 24-Jun 5:41 AM ET)
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Regenxbio trades on the NASDAQ stock market under the symbol RGNX.
As of July 29, 2026, RGNX stock price climbed to $9.62 with 1,030,237 million shares trading.
RGNX has a beta of 2.66, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.10 to the broad based SPY ETF.
RGNX has a market cap of $615.87 million. This is considered a Small Cap stock.
Last quarter Regenxbio reported $6 million in Revenue and -$1.72 earnings per share. This fell short of revenue expectation by $-19 million and missed earnings estimates by -$.32.
In the last 3 years, RGNX traded as high as $28.80 and as low as $5.04.
The top ETF exchange traded funds that RGNX belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
RGNX has underperformed the market in the last year with a price return of +14.4% while the SPY ETF gained +16.0%. However, in the short term, RGNX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +14.5% vs +2.8% return in SPY. But in the last 2 weeks, RGNX shares have been beat by the market, returning -21.6% compared to an SPY return of -3.4%.
RGNX support price is $9.00 and resistance is $10.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX shares will trade within this expected range on the day.
